KPV

Mechanism of action

KPV (Lys-Pro-Val) is the three-amino-acid C-terminal pharmacophore of α-melanocyte-stimulating hormone (α-MSH). Its anti-inflammatory profile is well characterised in cell-culture and rodent models and arises through at least two distinct molecular mechanisms. First, KPV enters intestinal epithelial cells and immune cells by exploiting the di/tripeptide transporter PepT1 (SLC15A1), which is expressed on the apical surface of enterocytes and on activated macrophages. Once inside the cell, KPV directly interferes with the NF-κB signalling cascade. Studies show reduced nuclear translocation of p65 and suppressed IκBα phosphorylation, leading to decreased transcription of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. This intracellular route distinguishes KPV from receptor-dependent anti-inflammatory agents, because it does not require melanocortin receptor binding for its primary gut mucosal action. Second, KPV lacks the N-terminal Ac-Ser-Tyr-Ser-Met sequence of full-length α-MSH that is required for high-affinity engagement of melanocortin-1 receptor (MC1R) on melanocytes. This structural absence means the pigmentary cascade — activation of tyrosinase and melanin synthesis — is not triggered. Research preparations of KPV therefore do not produce the skin-darkening effect associated with α-MSH or its longer fragments, making KPV a pharmacologically cleaner tool for studying melanocortin-pathway anti-inflammatory activity in isolation. In keratinocyte models, KPV has also been reported to suppress ICAM-1 expression and reduce inflammatory mediator release (IL-8, PGE2) in response to UV irradiation and bacterial lipopolysaccharide, suggesting utility in atopic and psoriasiform skin-inflammation research. The activation of melanocortin-type receptor MC3R and MC5R — which are expressed on immune cells independently of melanocytes — may contribute a secondary receptor-mediated component in some tissue contexts, though direct binding affinity data for KPV at these receptors are limited. A practical research consideration is that free KPV is rapidly hydrolysed by proteases encountered along the gastrointestinal tract, especially in the small intestine. Measured colonic tissue exposure following oral dosing of unprotected KPV in rodents is low. Nanoparticle encapsulation — particularly in hyaluronic-acid-based matrices that exploit CD44 receptor-mediated uptake on colonic epithelial cells — dramatically increases mucosal delivery and has become the dominant strategy for oral colitis research with KPV.

Hyaluronic-acid nanoparticle encapsulation of KPV (Laroui et al., Gastroenterology 2013) transformed oral delivery from near-zero colonic exposure to therapeutically relevant mucosal concentrations, establishing the nanoparticle platform as the standard research approach and producing robust efficacy in two independent IBD mouse models.

— Notable finding

Research history

The anti-inflammatory potential of α-MSH has been recognised since the 1970s, when studies in rodent models showed that systemic administration reduced fever and inhibited acute inflammatory responses. The systematic effort to identify which portion of the 13-amino-acid α-MSH peptide was responsible for these effects led, through the 1980s and 1990s, to structure-activity studies that progressively truncated the sequence from the N-terminus. Work by Lipton and Catania's groups in the 1990s identified the C-terminal tripeptide KPV as a minimal pharmacophore retaining anti-inflammatory activity in rodent endotoxin models. Crucially, the melanotropic activity associated with α-MSH resided in the N-terminal and central regions, so KPV emerged as a separation of anti-inflammatory function from pigmentary activity — a scientifically important distinction for safety and selectivity in potential therapeutic applications. The 2000s saw increasing interest in applying KPV to inflammatory bowel disease models. Work by Bhaskaran, Lawson, and colleagues explored KPV in chemically induced colitis, demonstrating mucosal protective effects. The pivotal translational advance came in 2013 when Laroui and colleagues at Emory University published a paper in Gastroenterology demonstrating that hyaluronic-acid nanoparticles loaded with KPV markedly improved delivery to colonic epithelial and macrophage targets compared with free peptide, and produced robust efficacy in dextran-sulfate-sodium (DSS) and TNBS colitis models. This work established nanoparticle encapsulation as the standard delivery strategy for oral KPV research and generated substantial academic interest in the peptide as a potential candidate for inflammatory bowel disease. In dermatology, the interest in KPV has paralleled ongoing research into the melanocortin system in skin inflammation. Studies from the early 2000s by Brzoska and Luger's group characterised KPV's ability to modulate cytokine release in human keratinocytes and Langerhans cells, supporting a topical anti-inflammatory application in atopic dermatitis and related conditions. KPV has not entered formal clinical drug development under that name, but elements of melanocortin-based anti-inflammatory research have informed drug programmes targeting MC3R and MC5R.

Summarised studies

Safety profile

KPV's small size (342 Da), lack of complex secondary structure, and status as an endogenous cleavage product of α-MSH all contribute to a generally favourable pre-clinical safety profile. In rodent acute toxicity studies, doses many times higher than those producing anti-inflammatory efficacy in colitis models have not produced mortality, organ-weight changes, or histopathological abnormalities in liver, kidney, or spleen. The minimal immunogenicity of a three-amino-acid peptide is expected on theoretical grounds and supported by the absence of antibody induction in studies lasting up to twelve weeks. The main safety consideration specific to KPV concerns the delivery vehicle rather than the peptide itself. Hyaluronic-acid nanoparticles are used in the majority of efficacy studies; the pharmacokinetics, biodistribution, and long-term fate of these carrier systems in vivo require separate evaluation. In Laroui and colleagues' 2013 work, the nanoparticle formulation was well tolerated and showed no apparent intestinal toxicity in DSS-colitis mice, but characterisation of accumulation in secondary organs was limited. Because KPV does not activate MC1R at research-relevant concentrations, systemic melanotropic effects are not expected. However, the potential for supraphysiological stimulation of MC3R and MC5R on immune cells at high injected doses has not been comprehensively characterised. Human safety data for KPV in isolation do not exist. Studies using full-length α-MSH in human endotoxaemia models provide indirect reassurance that the melanocortin anti-inflammatory pathway can be engaged without catastrophic immunosuppression, but direct human KPV pharmacology is unstudied. As with all research peptides, sterility, endotoxin content, and accurate concentration of laboratory preparations represent the most immediate practical safety variables.

UK regulatory status

KPV is not authorised as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and does not appear on any current MHRA list of approved active pharmaceutical ingredients for human therapeutic use. The compound is not named on the World Anti-Doping Agency (WADA) Prohibited List as of the 2025 iteration. Because KPV does not have anabolic, lipolytic, or endocrine-growth properties, it does not fall within the classes most commonly targeted by WADA (S0 non-approved substances, S2 peptide hormones). Researchers should nevertheless verify the current WADA list before conducting studies involving athletes. In the United Kingdom, possession of KPV for genuine in-vitro laboratory research is unrestricted. Supply or administration to humans as a treatment, or promotion of such use, would engage medicines legislation and require appropriate regulatory authorisation. No known MHRA enforcement actions against KPV specifically have been published.

Frequently asked questions